A decade of experience with patients with pituitary dysfunction has informed this 10th Anniversary volume of the HyppoCCS series. 

This ever-evolving area is brought up to date in this outstanding series of lectures by leading authorities who discuss basic and clinical topics covering the mechanisms of pituitary disease, peripheral hormone action and new therapies.   

Chapters cover pituitary developmental abnormalities and lessons learnt from growth hormone replacement in adults.  There is a valuable insight into the functional interaction between peripheral hormones and the pituitary gland in the control of the metabolic process.  In addition, comprehensive reviews on the role of androgens in women, the therapeutic potential of somatostatin analogues and glucocorticoid replacement are complemented by updates on Kallmann’s syndrome, craniopharyngiomas and the role of P27 in pituitary tumorigenesis.

Endocrine scientists and clinicians will find this thorough review represents excellence in the current published literature of pituitary disease.

Chapters

• HypoCCS: a decade of an outcomes assessment observational study
  S W J Lamberts,Erasmus Medical Center, Rotterdam, The Netherlands

• The Hypopituitary Control and Complications Study (HypoCCS) 1996–2005: a decade of care of adult GH deficient patients
  S M Webb, Hospital Santa Creu i Sant Pau, Autonomous University of Barcelona and CIBERER Unit, Barcelona, Spain; D Mo, Lilly Research Laboratories, Indiana, USA; D J Edwards, Lilly Research Centre, Surrey, UK; M L Hartman, Lilly Research Laboratories, Indiana, USA; W F Blum, Lilly Deutschland GmbH, Bad Homburg, Germany; H Jung, Lilly Deutschland GmbH, Bad Homburg, Germany; and A F Attanasio, Cascina del Rosone, Agliano Terme, Italy

• Molecular genetics in pediatric endocrinology and its impact on adult endocrinology: the GH–IGF axis
  R G Rosenfeld, Lucile Packard Foundation for Children’s Health, California, USA

• Impact of isolated growth hormone deficiency on the other pituitary gland derived hormonal axes
  P E Mullis, University Children’s Hospital, Inselspital, CH-3010 Bern, Switzerland

• Adult clinical phenotypes of patients with genetic causes of hypopituitarism
  R Reynaud, F Castinetti, A Saveanu, A Barlier, A Enjalbert and T Brue, Institut Fédératif Jean Roche, Université de la Méditerranée, Marseille, France

• Childhood onset adult growth hormone deficiency and hypopituitarism: a black box
  A F Attanasio, Cascina del Rosone, Agliano Terme, Italy

• Less common cases of GH deficiency (GHD) in the HypoCCS database
  C J Strasburger, Charité-Universitätsmedizin Campus Mitte, Berlin, Germany; C J Child, Lilly Research Centre, Surrey, UK; Y Li, Lilly Research Laboratories, Indiana, USA; D Mo, Lilly Research Laboratories, Indiana, USA;and A F Attanasio, Cascina del Rosone, Agliano Terme, Italy

• Heterogeneity of the empty sella syndrome
  M E Molitch, Northwestern University, Feinberg School of Medicine, Illinois, USA

• Pituitary dysfunction following traumatic brain injury
  C J Thompson, Beaumont Hospital and the RCSI Medical School, Dublin, Ireland

• The spectrum of hypophysitis
  A Bellastella, C Coronella, M Conte, G Bellastella, G Ruocco, L A Stile, G Tirelli, M Battaglia, A A Sinisi, A Bizzarro and A De Bellis, Second University of Naples, Naples, Italy

• Effect of gonadal steroids on growth hormone action
  K K Y Ho, St. Vincent’s Hospital, Sydney, Australia

• Metabolic syndrome, inflammation and cardiovascular risk
  J M Fernández-Real, Hospital Universitario de Girona ‘Dr Josep Trueta’, Girona, Spain

• Cerebrovascular disease in patients with pituitary tumours
  E M Erfurth and L Hagmar, Lund University Hospital, Lund, Sweden

• Growth hormone deficiency and replacement therapy in Japan: Results of placebo-controlled double-blind study and open-label extension study
  A Shimatsu, Kyoto Medical Center, Kyoto, Japan; S Tai, Lilly Research Laboratories Japan, Kobe, Japan; Y Kato, Shimane University, Izumo, Japan; H Kohno, Fukuoka Children’s Hospital, Fukuoka, Japan; T Tanaka, Tanaka Growth Clinic, Tokyo, Japan; A Teramoto, Nippon Medical School, Tokyo, Japan; and K Chihara, Nippon Medical School, Tokyo, Japan

• Safety surveillance in the Hypopituitary Control and Complications Study: Patterns of adverse events reporting
  S Ispas-Jouron, Vesancy, France; B J Crowe, Lilly Research Laboratories, Indiana, USA; R Bandy, Lilly Research Laboratories, Indiana, USA; and D J Edwards, Lilly Research Centre, Surrey, UK

• Presentation of the 2006 winner of the Eli Lilly HypoCCS award to Dr Christos S Mantzoros
  P C Sizonenko

• To fast or not to fast: the role of leptin in neuroendocrine regulation in energy deficiency states: An update
  I Kelesidis and C S Mantzoros, Harvard Medical School, Boston, USA

• Impact of patient-rated outcome assessment in pituitary disorders
  M Bullinger, University Hospital Hamburg-Eppendorf, Hamburg, Germany

• Quality of life as an outcome measure during GH treatment of adult GH deficient patients
  D J Edwards, Lilly Research Centre, Surrey, UK and D Mo Lilly Research Laboratories, Indiana, USA

• Quality of life in adult growth hormone deficiency
  R D Murray, St James’s Hospital, Leeds, UK; A Mukherjee, A Jostel and S M Shalet, Christie Hospital NHS Trust, Manchester, UK

Subject areas:  Endocrinology, Pituitary
Key words:  Pituitary, growth and development, hormone interventions
Market:  Clinicians, clinical researchers, lecturers and registrars in rheumatology or general medicine.